BUSINESS● LOWAug 13 · Aug 13, 2026, 8:59 PM
ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss
Seeking Alpha Tech
ARS Pharmaceuticals saw its stock drop following the abandonment of its DTC marketing for neffy and a miss on its Q2 EPS. This news impacts the company's market performance and strategic direction.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS42m agoGold market consolidating rather than entering bear market, Metals Focus analyst saysSeeking Alpha TechBUSINESS44m agoCollegium resolves Nucynta patent dispute with GrünenthalSeeking Alpha Tech